 - Patients must have been surgically or medically castrated; if the method of castration was luteinizing hormone-releasing hormone LHRH agonists leuprolide or goserelin, then the patient must be willing to continue the use of LHRH agonists; serum testosterone must be at castrate levels 50 ngdL at least 14 days prior to registration 